Emergency Use Authorization of Covid Vaccines — Safety and Efficacy Follow-up Considerations

Article discusses challenges of limited safety and efficacy data supporting COVID-19 vaccines and concludes a median 2-month follow-up after completion of an investigational COVID-19 vaccine regimen will provide necessary safety and effectiveness data to support distribution.

New England Journal of Medicine